Abstract
75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma--a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Autoantibodies / analysis
-
DNA / analysis
-
DNA Topoisomerases, Type I
-
HLA-DR3 Antigen / genetics
-
HLA-DR5 Antigen / genetics
-
Haplotypes / genetics
-
Humans
-
Nuclear Proteins / immunology
-
Probability
-
Pulmonary Fibrosis / etiology*
-
Pulmonary Fibrosis / immunology
-
Scleroderma, Systemic / complications*
-
Scleroderma, Systemic / immunology
Substances
-
Autoantibodies
-
HLA-DR3 Antigen
-
HLA-DR5 Antigen
-
Nuclear Proteins
-
Scl 70 antigen, human
-
DNA
-
DNA Topoisomerases, Type I